10-Q: NRC Health Q3 2025: Revenue Dips, New CFO Joins Amidst Strategic Investments

NRC Health reports a decline in Q3 2025 revenue and net income, while appointing Shane Harrison as its new CFO and increasing Total Recurring Contract Value.

Summary

• Revenue for the three months ended September 30, 2025, decreased by 3% to $34.6 million, down from $35.8 million in the prior year period.
• Net income for the three months ended September 30, 2025, fell by 28% to $4.1 million, compared to $5.7 million in the same period last year.
• Diluted Earnings Per Share (EPS) for Q3 2025 was $0.18, a decrease from $0.24 in Q3 2024.
• Total Recurring Contract Value (TRCV) increased by 8% to $141.7 million as of September 30, 2025, up from $131.6 million a year prior.
• Shane Harrison was appointed Executive Vice President and Chief Financial Officer, effective September 29, 2025, with an annual base salary of $400,000 and a $100,000 signing bonus.
• Mr. Harrison received an equity grant of 172,000 shares of restricted common stock, vesting over three years.
• Operating income for the three months ended September 30, 2025, decreased by 3% to $7.7 million.
• Cash provided by operating activities for the nine months ended September 30, 2025, decreased by 32% to $19.3 million.
• The company repurchased 618,264 shares of common stock for $9.3 million during Q3 2025, exhausting the 2025 Program authorization.
• Capital expenditures for the nine months ended September 30, 2025, totaled $9.6 million, primarily for building renovations and computer software development.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant declines in revenue, net income, and EPS for both the quarter and year-to-date periods. Increased operating expenses and interest costs further impacted profitability. While TRCV growth and a new CFO are positive, the immediate financial performance is concerning, leading to a working capital deficit.

Positives

• Total Recurring Contract Value (TRCV) increased by 8% to $141.7 million, indicating future revenue potential.
• Direct expenses decreased by 19% in Q3 2025, primarily due to lower conference costs and benefits from workforce reduction and automation implemented in Q4 2024.
• The appointment of Shane Harrison as EVP and CFO brings a strong background in finance and strategic planning.
• The company maintains strong liquidity with $30.0 million available on its Revolving Loan and an additional $27.6 million on its Delayed Draw Term Loan (excluding accordion feature).
• The company is in compliance with all financial covenants under its Credit Agreement as of September 30, 2025.

Negatives

• Revenue decreased by 3% in Q3 2025 and 4% for the nine months ended September 30, 2025, primarily due to decreased recurring revenue in the existing client base.
• Net income decreased by 28% in Q3 2025 and 46% for the nine months ended September 30, 2025.
• Diluted EPS decreased from $0.24 to $0.18 in Q3 2025 and from $0.76 to $0.43 for the nine months ended September 30, 2025.
• Selling, general and administrative expenses increased by 12% in Q3 2025 and 21% for the nine months ended September 30, 2025, mainly due to new executive compensation arrangements.
• Total other expense increased by 114% in Q3 2025, primarily due to higher interest expense from increased borrowings on the Delayed Draw Term Loan.
• The effective tax rate increased significantly to 34% in Q3 2025 and 33% for the nine months ended September 30, 2025, due to deductible limitations on executive compensation related to cash bonuses.
• Cash provided by operating activities decreased by 32% for the nine months ended September 30, 2025, due to lower net income and working capital changes.
• The company reported a working capital deficit of $18.2 million as of September 30, 2025, an increase from $16.3 million at December 31, 2024.

Risks

• The possibility of non-renewal of client service contracts, reductions in services purchased or prices, and failure to retain key clients.
• The ability to compete in highly competitive markets with new entrants and consolidation, leading to increased price pressure and expenses.
• The possibility that solutions and technology do not perform as expected.
• The possibility that acquisitions and partnerships do not achieve the increased demand/profitability expected.
• The likelihood that a pandemic will adversely affect operations, sales, earnings, financial condition, and liquidity.
• The likelihood that global conflicts or tariffs will adversely affect operations, sales, earnings, financial condition, and liquidity.
• The effects of an economic downturn.
• The impact of consolidation in the healthcare industry.
• The impact of federal healthcare and budget legislation, executive orders, cost-saving measures, and other regulatory changes.
• The ability to attract and retain key managers and other personnel.
• The possibility that intellectual property and other proprietary information technology could be copied or independently developed by competitors.
• The ability to maintain effective internal controls.
• The possibility for failures or deficiencies in the information technology platform.
• The possibility that the company or its third-party providers could be subject to cyber-attacks, security breaches, or computer viruses.

Future Outlook

The company expects revenue growth to follow changes in Total Recurring Contract Value (TRCV) within the next few quarters, assuming sustained TRCV growth. It plans to continue investing in innovative solutions for clients, which may cause direct expenses to fluctuate. The company believes its existing liquidity sources will be sufficient to meet projected capital and debt maturity needs for the foreseeable future. The recently signed 'One Big Beautiful Bill Act' is not expected to have a material impact on financial statements, but will result in expanded income tax disclosures starting in 2025.

Management Comments

• "Our commitment to Human Understanding helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship."
• "We believe access to and analysis of our extensive consumer-driven information is increasingly valuable as healthcare providers need to better understand and engage the people they serve to create long-term relationships and build loyalty."
• "We expect to continue to invest in providing innovative solutions to our clients, which could cause direct expenses to fluctuate as a percentage of revenue."
• "Notwithstanding our working capital deficit on September 30, 2025, we believe that our existing sources of liquidity, including cash and cash equivalents, borrowing availability, and operating cash flows will be sufficient to meet our projected capital and debt maturity needs for the foreseeable future."

Industry Context

NRC Health operates in the healthcare industry, which is experiencing evolving payment models that drive providers and payers towards more collaborative and integrated service models. The company's AI-enabled subscription-based solutions, focused on patient experience, service recovery, employee engagement, and brand loyalty, position it to capitalize on the increasing need for healthcare organizations to understand and engage individuals for long-term relationships and loyalty. The company's emphasis on 'Human Understanding' aligns with a broader industry trend towards patient-centric care.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in certain claims and litigation arising in the normal course of business. Management assesses the probability of loss and recognizes a liability when probable and estimable.
• Management does not believe the final disposition of claims at September 30, 2025, will have a material adverse effect on the consolidated financial position, results of operations, or liquidity.
• Legal proceedings, claims, inquiries, and investigations can impose significant burdens on management and employees, include costly defense and settlement costs, and harm reputation and brand.

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Impacted by decreased EPS and net income, but also benefit from continued quarterly dividends and the potential for future growth indicated by TRCV increase. The stock repurchase program provides some support.
• Employees: Benefits from new compensation arrangements for CEO and executive leaders, but also experienced workforce reductions and automation in Q4 2024. The new CFO appointment brings leadership stability.
• Customers: Benefit from ongoing investment in AI-enabled subscription solutions and product development aimed at enhancing patient experience and loyalty.
• Creditors: The company is in compliance with financial covenants under its Credit Agreement, providing assurance regarding debt obligations. The debt is collateralized by substantially all company assets.
• Suppliers: No specific impact mentioned, but general business operations continue.

Next Steps

• Shane Harrison will serve as Executive Vice President and Chief Financial Officer, reporting to the CEO and having a direct line to the Audit Committee.
• The company will continue to evaluate the full effects of the 'One Big Beautiful Bill Act' on its estimated annual effective tax rate and cash tax position.
• The company will continue to monitor recently issued accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-06) for their potential impact on financial statements and disclosures.
• The Board of Directors will continue to consider whether to declare a dividend and the amount on a quarterly basis.

Key Dates

Recommendation

While the company experienced significant declines in revenue, net income, and EPS for the quarter and year-to-date, the 8% increase in Total Recurring Contract Value (TRCV) suggests potential for future revenue growth. The appointment of a new CFO and ongoing investments in AI-enabled solutions and infrastructure indicate a strategic focus on long-term development. However, the current financial underperformance, increased operating expenses, higher interest costs, and a growing working capital deficit warrant caution. A 'hold' recommendation allows investors to monitor if the TRCV growth translates into improved financial results and if the strategic investments yield expected returns, without taking on additional risk given the current headwinds.

Keywords

Healthcare technology, Patient experience, CFO appointment, SEC filing, Quarterly results, Financial performance, Subscription services, Restricted stock, Debt financing, Stock repurchase